Lion Point Capital, LP — 13F Holdings & Portfolio
CIK 1643354 · latest 13F-HR filed 2026-08-14
Lion Point Capital, LP manages $20.9M in 13F-reported U.S. long-equity assets across 35 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are CUE (7.99%), PRAX (7.13%), MLTX (6.29%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 1 new position, exited 1, added to 21, and trimmed 7.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
SUITE 2609
NEW YORK, NY 10152
$20.9M
Long-equity book
35
Distinct positions
2026-06-30
Filed 2026-08-14
+1 / −1 / ↑21 / ↓7
vs 2026-03-31
| Name | Title / Status | Ownership | Type |
|---|
Top Adds (vs prior quarter)
- COMPASS PATHWAYS PLC$689.6K +155.9%
- FENNEC PHARMACEUTICALS INC$517.2K +74.8%
- UNIQURE NV$436.7K +181.7%
- BIOHAVEN LTD$331.9K +75.9%
- LANTHEUS HLDGS INC$193.0K +46.3%
Top Trims
- JASPER THERAPEUTICS INC-$211.7K -52.0%
- GERON CORP-$121.4K -14.1%
- ARDELYX INC-$114.5K -14.9%
- SAREPTA THERAPEUTICS INC-$108.0K -17.4%
- SYNDAX PHARMACEUTICALS INC-$54.0K -6.4%
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | CUE BIOPHARMA INC | CUE | 22978P205 | $1.7M | 7.99% | 52,928 | SH |
| 2 | PRAXIS PRECISION MEDICINES I | PRAX | 74006W207 | $1.5M | 7.13% | 4,450 | SH |
| 3 | MOONLAKE IMMUNOTHERAPEUTICS | MLTX | 61559X104 | $1.3M | 6.29% | 67,500 | SH |
| 4 | FENNEC PHARMACEUTICALS INC | FENC | 31447P100 | $1.2M | 5.78% | 112,434 | SH |
| 5 | ROYALTY PHARMA PLC | RPRX | G7709Q104 | $1.2M | 5.74% | 21,400 | SH |
| 6 | COMPASS PATHWAYS PLC | CMPS | 20451W101 | $1.1M | 5.41% | 80,000 | SH |
| 7 | MILESTONE PHARMACEUTICALS IN | MIST | 59935V107 | $1.1M | 5.26% | 820,000 | SH |
| 8 | BENITEC BIOPHARMA INC | BNTC | 08205P209 | $829.6K | 3.97% | 62,000 | SH |
| 9 | SYNDAX PHARMACEUTICALS INC | SNDX | 87164F105 | $787.0K | 3.76% | 36,000 | SH |
| 10 | BIOHAVEN LTD | BHVN | G1110E107 | $769.3K | 3.68% | 51,700 | SH |
| 11 | GERON CORP | GERN | 374163103 | $739.8K | 3.54% | 578,000 | SH |
| 12 | UNIQURE NV | QURE | N90064101 | $677.1K | 3.24% | 14,700 | SH |
| 13 | ARDELYX INC | ARDX | 039697107 | $656.1K | 3.14% | 128,650 | SH |
| 14 | LANTHEUS HLDGS INC | LNTH | 516544103 | $610.2K | 2.92% | 5,500 | SH |
| 15 | DISC MEDICINE INC | IRON | 254604101 | $592.4K | 2.83% | 8,100 | SH |
| 16 | SAREPTA THERAPEUTICS INC | SRPT | 803607100 | $512.1K | 2.45% | 28,500 | SH |
| 17 | HUMACYTE INC | HUMA | 44486Q103 | $507.3K | 2.43% | 650,000 | SH |
| 18 | KURA ONCOLOGY INC | KURA | 50127T109 | $504.6K | 2.41% | 46,000 | SH |
| 19 | VIATRIS INC | VTRS | 92556V106 | $439.9K | 2.10% | 27,700 | SH |
| 20 | DYNE THERAPEUTICS INC | DYN | 26818M108 | $399.8K | 1.91% | 18,000 | SH |
| 21 | BRIDGEBIO PHARMA INC | BBIO | 10806X102 | $372.4K | 1.78% | 5,000 | SH |
| 22 | EDGEWISE THERAPEUTICS INC | EWTX | 28036F105 | $369.7K | 1.77% | 9,100 | SH |
| 23 | PACIRA BIOSCIENCES INC | PCRX | 695127100 | $342.5K | 1.64% | 13,500 | SH |
| 24 | REGENXBIO INC | RGNX | 75901B107 | $318.7K | 1.52% | 26,600 | SH |
| 25 | ROCKET PHARMACEUTICALS INC | RCKT | 77313F106 | $294.1K | 1.41% | 86,000 | SH |
| 26 | JANUX THERAPEUTICS INC | JANX | 47103J105 | $291.8K | 1.40% | 19,000 | SH |
| 27 | MINERALYS THERAPEUTICS INC | MLYS | 603170101 | $283.3K | 1.36% | 10,500 | SH |
| 28 | GH RESEARCH PLC | GHRS | G3855L106 | $274.2K | 1.31% | 10,200 | SH |
| 29 | SERES THERAPEUTICS INC | MCRB | 81750R201 | $249.1K | 1.19% | 31,570 | SH |
| 30 | AZENTA INC | AZTA | 114340102 | $247.5K | 1.18% | 9,700 | SH |
| 31 | JASPER THERAPEUTICS INC | JSPR | 471871202 | $195.8K | 0.94% | 465,000 | SH |
| 32 | INNOVIVA INC | INVA | 45781M101 | $186.2K | 0.89% | 8,200 | SH |
| 33 | INNATE PHARMA S A | IPHA | 45781K204 | $149.3K | 0.71% | 81,151 | SH |
| 34 | ARCUTIS BIOTHERAPEUTICS INC | ARQT | 03969K108 | $137.7K | 0.66% | 5,250 | SH |
| 35 | SPRUCE BIOSCIENCES INC | SPRB | 85209E208 | $54.0K | 0.26% | 1,000 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $20.9M | 35 | 0001013594-26-000908 |
| 2026-03-31 | 2026-05-15 | $16.7M | 35 | 0001013594-26-000605 |
| 2025-12-31 | 2026-02-17 | $19.3M | 39 | 0001013594-26-000252 |
| 2025-09-30 | 2025-11-14 | $17.6M | 27 | 0001013594-25-001425 |